Trinity Biotech PLC (TRIB) - NASDAQ
  • Thu, Jul. 21, 8:43 AM
    • Trinity Biotech (TRIB) Q2 results: Revenues: $26.3M (+8.2%); Operating Income: $2.4M (-20.0%); Net Income: $2.1M (-22.2%); EPS: $0.09 (-10.0%); Quick Assets: $84.9M (-12.3%).
    • No guidance given.
    | Thu, Jul. 21, 8:43 AM
  • Thu, Jul. 21, 8:25 AM
    • Trinity Biotech (NASDAQ:TRIB): Q2 EPS of $0.09 beats by $0.03.
    • Revenue of $26.29M (+8.4% Y/Y) beats by $1.49M.
    • Press Release
    | Thu, Jul. 21, 8:25 AM
  • Tue, Apr. 19, 9:01 AM
    • Trinity Biotech (TRIB) Q1 results: Revenues: $23.5M (-6.7%); R&D Expense: $1.1M (+10.0%); SG&A: $7M (+11.1%); Operating Income: $1.8M (-58.1%); Net Loss: ($1.3M) (-132.5%); Loss Per Share: ($0.06) (-135.3%); Non-GAAP EPS: $0.06 (-64.7%); Quick Assets: $96.8M (-5.1%).
    • No guidance given.
    | Tue, Apr. 19, 9:01 AM
  • Tue, Apr. 19, 8:34 AM
    • Trinity Biotech (NASDAQ:TRIB): Q1 EPS of $0.06 misses by $0.02.
    • Revenue of $23.5M (-6.9% Y/Y) misses by $0.72M.
    • Press Release
    | Tue, Apr. 19, 8:34 AM
  • Thu, Mar. 3, 8:58 AM
    • Trinity Biotech (NASDAQ:TRIB): Q4 EPS of $0.08 misses by $0.01.
    • Revenue of $24.9M (-6.7% Y/Y) misses by $0.91M.
    • The company suspends its annual dividend payment to deploy capital for share buyback.
    • Press Release
    | Thu, Mar. 3, 8:58 AM
  • Oct. 22, 2015, 12:47 PM
    | Oct. 22, 2015, 12:47 PM | 1 Comment
  • Oct. 22, 2015, 10:49 AM
    • Trinity Biotech (TRIB +16.7%) Q3 results: Revenues: $25.8M (-5.1%); COGS: $13.8M (-2.8%); R&D Expense: $1.3M (+18.2%); SG&A: $7.5M (+7.1%); Operating Income: $3M (-34.8%); Net Income: $12.3M (+179.5%); Earnings/ADR: $0.097 (-47.3%); Quick Assets: $104.3M (+999%).
    • No guidance given.
    | Oct. 22, 2015, 10:49 AM
  • Oct. 22, 2015, 8:44 AM
    • Trinity Biotech (NASDAQ:TRIB): Q3 EPS of $0.08 misses by $0.01.
    • Revenue of $25.8M (-5.1% Y/Y) beats by $0.38M.
    | Oct. 22, 2015, 8:44 AM | 2 Comments
  • Jul. 28, 2015, 9:45 AM
    • Trinity Biotech (TRIB -3.7%) Q2 results: Revenues: $24.3M (-6.5%); COGS: $12.9M (-4.4%); R&D Expense: $1.3M (+8.3%); SG&A: $6.7M (+4.7%); Operating Income: $3M (-34.8%); Net Income: $2.7M (-37.2%); Earrnings / ADR: $0.10 (-44.4%); Quick Assets: $110.3M (+999%).
    • No guidance given.
    | Jul. 28, 2015, 9:45 AM
  • Jul. 28, 2015, 9:31 AM
    • Trinity Biotech (NASDAQ:TRIB): Q2 EPS of $0.10 misses by $0.04.
    • Revenue of $24.3M (-6.5% Y/Y) misses by $1.89M.
    | Jul. 28, 2015, 9:31 AM | 1 Comment
  • Jul. 2, 2015, 4:07 PM
    • The FDA issues 510(k) clearance for privately-held Theranos' diagnostic testing system and its test for herpes simplex 1 IgG, the 153rd test that the company provides for less than $10 in its service offering. The automated system the company has developed utilizes microfluidics to perform a wide array of tests on small volume blood samples, including those from a finger stick. Some observers believe Theranos will upend the clinical diagnostics industry with its modest costs. The herpes test, for example, will sell for only $9.07 compared to ~$175 from leading reference labs.
    • Theranos founder and CEO Elizabeth Holmes is one the newest celebrity entrepreneurs. Based on the company's current valuation, she is the youngest self-made female billionaire in U.S. history.
    • Some diagnostics-related tickers: (NYSE:ABT) (OTCQX:RHHBY) (NASDAQ:QDEL) (NYSE:BIO) (NASDAQ:QGEN) (NASDAQ:CPHD) (NASDAQ:CEMI) (NASDAQ:TRIB) (NASDAQ:AXDX) (NASDAQ:CBMX) (NYSE:TMO)
    | Jul. 2, 2015, 4:07 PM
  • Apr. 30, 2015, 9:24 AM
    • Trinity Biotech (NASDAQ:TRIB) declares $0.22/share annual dividend, in line with previous.
    • Forward yield 1.31%
    • Payable June 30; for shareholders of record June 9; ex-div June 5.
    | Apr. 30, 2015, 9:24 AM
  • Apr. 30, 2015, 8:29 AM
    • Trinity Biotech (NASDAQ:TRIB): Q1 EPS of $0.17 in-line.
    • Revenue of $25.24M (+0.9% Y/Y) misses by $0.69M.
    | Apr. 30, 2015, 8:29 AM
  • Apr. 9, 2015, 1:15 PM
    • Dublin, Ireland-based Trinity Biotech (TRIB +1.6%) closes its offering of $115M aggregate principal amount of 4.00% Exchangeable Senior Notes due 2045, including the full exercise of the initial purchasers' option to buy an additional $15M of the notes.
    • Net proceeds of ~$111M will fund future acquisitions and general corporate purposes.
    • Previously: Trinity Biotech initiates convertible debt offering (April 2)
    | Apr. 9, 2015, 1:15 PM
  • Apr. 2, 2015, 5:30 PM
    • Trinity Biotech (NASDAQ:TRIB) commences a private $100M convertible debt offering to institutional investors. The Exchangeable Senior Notes due 2045 will bear interest of 4.00% paid semi-annually. Initial purchasers will have a 30-day option to buy an additional $15M of the Notes. The exchange rate will be 45.1488 ADSs per $1,000 principal amount ($22.15 per ADS).
    • Net proceeds will fund future acquisitions and general corporate purposes.
    | Apr. 2, 2015, 5:30 PM
  • Apr. 2, 2015, 12:45 PM
    | Apr. 2, 2015, 12:45 PM | 2 Comments
Company Description
Trinity Biotech Plc develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. Its products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the... More
Sector: Healthcare
Industry: Diagnostic Substances
Country: Ireland